NEO NEOGENOMICS INC

company

SEC Filings & Insider Trading Activity 2026

Business Overview

• • Core business: oncology-focused diagnostic testing and consultative services, including molecular and precision cancer testing
• • Emphasis on growth in therapy selection and Molecular Residual Disease (MRD) testing with launches under a 2026 launch excellence program
• • Strategic expansion into community oncology market leveraging partnerships for accelerated topline growth
• • Largest molecular testing panels include PanTracer and Neo Comprehensive portfolios with NGS capabilities; Inivata acquisition (2021) bolsters liquid biopsy MRD tech
• • 2026 focus on driving operational efficiency via automation, customer experience improvements, and culture with enhanced collaboration and accountability

Risk Factors

• • FDA potential regulation of Laboratory Developed Tests requiring clinical trials and approvals, risking operational disruptions and costs
• • Global conflicts and political unrest posing business disruption risks with no specific regional revenue exposure disclosed
• • Capacity constraints risk from inability to scale personnel and systems impacting turnaround times and client retention
• • Intense competition from Quest Diagnostics, Guardant Health, and Myriad Genetics increasing price pressure and market share risk
• • Servicing $2028 Convertible Notes may strain cash flow and limit financial flexibility impacting operational funding

Management Discussion & Analysis

• • Revenue $727.3M in 2025, up 10.1% YoY or $66.8M, driven by higher test volumes, higher value tests, reimbursement, and Pathline acquisition
• • Gross profit $314.3M, margin 43.2% in 2025 vs 43.9% in 2024, a 0.7% margin decline mainly from Pathline acquisition and rising costs
• • Best segment: clinical molecular and NGS testing driving growth; worst segment: lower non-clinical revenue due to macro clinical trial trends
• • Adjusted EBITDA $43.4M in 2025, up 9.5% or $3.7M YoY; G&A $273.3M (37.6% of revenue) increased 5.2% or $13.6M; sales & marketing $92.0M up 8.7%
• • No restructuring charges in 2025 vs $6.7M in 2024; R&D expense $37.1M (5.1% of revenue), up 19%; expecting increased R&D investment going forward
• • Management plans to grow via precision diagnostics, therapy selection, MRD testing, community oncology expansion, and efficiency through automation
• • Regulatory risk: FDA LDT oversight uncertain after 2025 court ruling vacating FDA rule; potential future FDA changes could increase compliance costs
• • No significant expected 2026 revenue impact from regulatory changes; continued investments in test menu expansion, IT, automation, and sales force growth

Risk Factors

• • No new risk factors added this quarter; risk profile consistent with 2024 Form 10-K
• • Most materially updated risk: no specific changes disclosed in current 10-Q
• • Regulatory risk: ongoing compliance with evolving FDA and CMS regulations critical for lab services reimbursement
• • Operational risk: dependency on timely integration of acquisitions affecting near-term revenue growth
• • Financial risk: liquidity management pivotal given $100M debt maturing in next 18 months

What are the latest NEO SEC filings in 2026?

NEOGENOMICS INC (NEO) has filed a 10-K annual report on February 17, 2026, a 10-Q quarterly report on October 28, 2025, an 8-K current report on July 28, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.

When did NEO file its most recent 10-K annual report?

NEOGENOMICS INC (NEO) filed its most recent 10-K annual report on February 17, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.

How do I view NEO 10-Q quarterly reports?

NEOGENOMICS INC (NEO)'s most recent 10-Q quarterly report was filed on October 28, 2025. SignalX displays every NEO 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.

What 8-K current reports has NEO filed recently?

NEOGENOMICS INC (NEO)'s most recent 8-K was filed on July 28, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.

Where can I find NEO insider trading activity (Form 4)?

SignalX aggregates every NEO Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.

How often does NEO file with the SEC?

NEOGENOMICS INC (NEO) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new NEO filing with AI-powered analysis.

What is the difference between 10-K, 10-Q, and 8-K SEC filings?

A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs, such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for NEOGENOMICS INC (NEO).

What is NEO's SEC CIK number?

NEOGENOMICS INC (NEO)'s SEC CIK (Central Index Key) number is 1077183. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1077183 to look up all NEO filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.

Where can I find NEO return on equity (ROE) and financial data?

SignalX extracts XBRL financial data from NEOGENOMICS INC (NEO) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.